This sounds like an extremely disruptive breakthrough for Oncosec. So far the market has been uninterested in the "talk" of a multi-gene construct. Lets hope the actual data shakes the market up when it comes out next month. This is exactly the type of news we need to get the recovery ball rolling here. Thanks for elaborating on this hschlauch.